Breaking News

Gallus, Symphogen in Clinical Manufacturing Pact

By Kristin Brooks | February 26, 2014

To manufacture Symphogen’s antibody mixture product candidates

Gallus BioPharmaceuticals has signed a manufacturing agreement with Symphogen, A/S for the process transfer and clinical stage cGMP manufacture of Symphogen’s antibody mixture product candidates. Gallus will employ the GE Healthcare Life Sciences Flex Factory, a single-use biomanufacturing platform, at its headquarters in St. Louis to manufacture product candidates.
 
“Gallus is delighted to partner with Symphogen in the process development and clinical supply of their antibody mixture candidates. Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized mAb mixtures manufactured in a single batch. Gallus’ expertise in process development and scale-up will ensure high quality molecules are delivered to the clinic,” said Mark R. Bamforth, Gallus’ president and chief executive officer.
 
“We are pleased to work with Gallus, a very experienced CMO with an extensive background in the cGMP manufacture of antibodies, ranging from early stage clinical programs to the commercial supply of approved therapeutics. We look forward to working together to advance our innovative cancer therapeutic programs,” said Kirsten Drejer, chief executive officer of Symphogen.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision